

<b>L Number</b>	<b>Hits</b>	<b>Search Text</b>	<b>DB</b>	<b>Time stamp</b>
2	43	(cysteine with inhibitor\$) and transdermal\$ and ((isopropyl with myristate) or (polyoxyethylene with oleyl))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/01 12:06
3	62	(cysteine with inhibitor\$) and transdermal\$ and (((isopropyl with myristate) or (polyoxyethylene with oleyl)) or ((penetration absorption) with enhancer))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/01 12:07
4	64	(cysteine with inhibitor\$) and (transdermal\$ patch) and (((isopropyl with myristate) or (polyoxyethylene with oleyl)) or ((penetration absorption) with enhancer))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/03/01 12:13
-	3467	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 10:27
-	399	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((enhancer) with (absorption penetration)) and (eye vitreous retina) and (drug pharmaceutical agent steroid)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 10:39
-	159	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((enhancer) with (absorption penetration)) and (eye vitreous retina) and (drug pharmaceutical agent steroid) and cysteine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 10:40
-	8	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((enhancer) with (absorption penetration)) and (eye vitreous retina) and (drug pharmaceutical agent steroid) and (cysteine with inhibit\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 10:41

-	55	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and (drug pharmaceutical agent steroid) and (cysteine with inhibit\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 10:45
-	445	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((polyoxyethylene with oleyl) or (isopropyl with myristate))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 11:04
-	252	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((polyoxyethylene with oleyl) or (isopropyl with myristate)) and (cataract anti\$inflammatory-inflammatory	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 11:18
-	82	viral immunosuppressant immunosuppressive glutamate) and acrylic ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((polyoxyethylene with oleyl) or (isopropyl with myristate)) and (cataract anti\$inflammatory inflammatory viral immunosuppressant immunosuppressive glutamate) and acrylic and (eye retina\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 11:19
-	39	ophthalmic and (transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((polyoxyethylene with oleyl) or (isopropyl with myristate)) and (cataract anti\$inflammatory inflammatory viral immunosuppressant immunosuppressive glutamate) and (acrylic "pe-300" (acrylic with (copolymer polymer matrix)) (silicone with matrix) slastic (silicone with elastomer) dimethylsiloxane cariflex jsr5000) and (eye retina\$ glaucoma) and adhesive	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 12:03

-	383	(transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((polyoxyethylene with oleyl) or (isopropyl with myristate)) and (cataract anti\$inflammatory inflammatory viral immunosuppressant immunosuppressive glutamate) and (acrylic "pe-300" (acrylic with (copolymer polymer matrix)) (silicone with matrix) slastic (silicone with elastomer) dimethylsiloxane cariflex jsr5000) and (eye retina\$ glaucoma ophthalmic ocular) and layer\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 14:11
-	304	(transdermal or transdermally or epidermal or epidermally or cutaneously or cutaneous or transcutaneous or transcutaneously or (trans-cutaneous or trans-cutaneously) or (trans adj cutaneous or trans adj cutaneously)) and ((polyoxyethylene with oleyl) or (isopropyl with myristate)) and (cataract anti\$inflammatory inflammatory viral immunosuppressant immunosuppressive glutamate) and (acrylic "pe-300" (acrylic with (copolymer polymer matrix)) (silicone with matrix) slastic (silicone with elastomer) dimethylsiloxane cariflex jsr5000) and (eye retina\$ glaucoma ophthalmic ocular) and layer\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/27 14:42
-	51	ophthalmic and transdermal and ((penetration absorption) with enhancer) and (pharmaceutical (active with agent) glutamate (cysteine near3 inhibitor) inflammatory antiinflammatory cataract) and (((acrylate acrylic) same polymer) or (silicone same polymer))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/28 11:38
-	29	ophthalmic and transdermal and ((penetration absorption) with enhancer) and (drug pharmaceutical (active with agent) glutamate (cysteine near3 inhibitor) inflammatory antiinflammatory cataract) and (((acrylate acrylic) same polymer) or (silicone same polymer)) and adhesive	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/28 11:45
-	86	ophthalmic and (percutaneous transdermal) and (((penetration absorption) with enhancer) or ((polyoxyethylene near2 oleyl) (isopropyl near2 myristate))) and (drug medicament pharmaceutical (active with agent) glutamate (cysteine near3 inhibitor) inflammatory antiinflammatory cataract) and (((acrylate acrylic) same polymer) or (silicone same polymer))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/28 11:52

-	73	ophthalmic and (transdermal\$) and (((penetration absorption) with enhancer) or ((polyoxyethylene near2 oleyl) (isopropyl near2 myristate))) and (drug medicament pharmaceutical (active with agent) glutamate (cysteine near3 inhibitor) inflammatory antiinflammatory cataract) and (((acrylate acrylic) same polymer) or (silicone same polymer))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/02/28 11:56
---	----	--	---	---------------------

**PALM INTRANET**Day : Saturday  
Date: 3/1/2003  
Time: 13:11:27

## Inventor Information for 10/089431

Inventor Name	City	State/Country
TOJO, KAKUJI	FUKUOKA	JAPAN
ISOWAKI, AKIHARU	HYOGO	JAPAN

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity Data](#)[Foreign t](#)Search Another: Application#  or Patent#  PCT /  /  or PG PUBS #  Attorney Docket #  Bar Code #  

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

**Inventor Name Search Result**

Your Search was:

Last Name = TOJO

First Name = KAKUJI

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<a href="#">08408024</a>	<a href="#">5694196</a>	150	03/21/1995	EXPERIMENTAL INSTRUMENT FOR EXAMINING PERMEABILITY OF A FLOWING CORNEA AND AN EXPERIMENTAL UNIT USING SAID EXPERIMENTAL INSTRUMENT	TOJO , KAKUJI
<a href="#">06751126</a>	<a href="#">4690683</a>	150	07/02/1985	TRANSDERMAL VARAPAMIL DELIVERY DEVICE	TOJO , KAKUJI
<a href="#">08352379</a>	<a href="#">5599175</a>	150	12/08/1994	MICRO FLOW-CONTROLLING PUMP	TOJO , KAKUJI
<a href="#">08610789</a>	<a href="#">5866141</a>	150	03/11/1996	PATCH PREPARATIONS FOR TREATING PLANTS	TOJO , KAKUJI
<a href="#">10089431</a>	Not Issued	030	03/28/2002	OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEAOUS ABSORPTION	TOJO, KAKUJI

**Inventor Search Completed:** No Records to Display.

	<b>Last Name</b>	<b>First Name</b>	
<b>Search Another: Inventor</b>	<input type="text" value="TOJO"/>	<input type="text" value="KAKUJI"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

**PALM INTRANET**Day : Saturday  
Date: 3/1/2003  
Time: 13:11:55**Inventor Name Search Result**

Your Search was:

Last Name = ISOWAKI

First Name = AKIHARU

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>10089431</u>	Not Issued	030	03/28/2002	OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEAOUS ABSORPTION	ISOWAKI, AKIHARU

**Inventor Search Completed: No Records to Display.**

	<b>Last Name</b>	<b>First Name</b>	
<b>Search Another: Inventor</b>	<input type="text" value="ISOWAKI"/>	<input type="text" value="AKIHARU"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)